# US 2012/0252773 A1 · Method and composition for inhibiting cell proliferation and angiogenesis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252773 A1
- Document ID: US20120252773A1
- Status: Published application
- Kind: A1
- Application number: 13/457,416
- Filed: 2012-04-26
- Published: 2012-10-04
- Earliest claimed: 2005-04-18
- Inventors: Khalid Amin; Joy M. Calaoagan; Wan-Ru Chao; Peter D. Hobbs; Keith R. Laderoute; Richard H. Peters; Masato Tanabe
- Web page: https://patentgrep.com/patent/US20120252773A1

## CPC

- A61K 31/56: Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method is provided for treating a patient with a medical condition that involves angiogenesis or HIF-1 overexpression with a compound having the structure of formula (I) wherein Z, x, y, and R1 through R11 are as defined herein.

## Claims

### Claim at position 1

1-20. (canceled)

### Claim 21

A method for inhibiting HIF-1α comprising:
(a) contacting cells with a compound of formula (I) sufficient to inhibit HIF-1α in the cells, wherein formula (I) is:
wherein:
Z is —O-(L)q-, —S-(L)q-, or —NR12-(L)q- wherein q is zero or 1, L is monocyclic aryl optionally substituted with up to 4 substituents independently selected from hydrogen, hydroxyl, C1-C6 alkoxy, C1-C6 alkyl, halo, amino, and C1-C6 alkyl-substituted amino, wherein any two adjacent substituents on L may be taken together to form an optionally substituted cyclic structure, and R12 is hydrogen or C1-C6 alkyl;
x is an integer in the range of 1 to about 6 inclusive;
when q is zero, y is an integer in the range of 2 to about 6 inclusive, and when q is 1, y is an integer in the range of 1 to about 6 inclusive;
R1 and R2 are independently selected from hydrogen and C1-C6 alkyl, or can be taken together to form an optionally substituted nitrogen heterocycle containing zero to two additional heteroatoms;
R3 is selected from hydrogen, hydroxyl, C1-C6 alkoxy, halo, C1-C3 alkyl, C2-C3 alkenyl, monocyclic aryl, and monocyclic aryl-substituted C1-C3 alkyl;
R4 is hydrogen or C1-C6 alkyl;
R5 is selected from hydrogen, C1-C6 alkoxy, halo, cyano, C1-C6 alkyl, and C2-C6 alkenyl;
R6 is selected from hydrogen, C1-C6 alkyl, C2-C12 acyl, and —SO2NH2;
R7 is selected from hydrogen, halo, C1-C6 alkyl, C2-C6 alkenyl, —OR13 and —SR13 where R13 is C1-C6 alkyl, C2-C6 acyl, or aryl;
R8 is hydrogen, C1-C6 alkoxy, or hydroxyl;
R9 is selected from hydrogen, hydroxyl, C1-C6 alkyl, C2-C6 alkenyl, aryl, and alkaryl; and
R10 and R11 are independently selected from hydrogen, C1-C6 alkoxy, and C1-C6 alkyl,
or a pharmaceutically acceptable salt thereof; and
wherein (i) the method further comprises the step of detecting in the cells HIF-1α expression, or (ii) the contacting step comprises administering a therapeutically effective amount of the compound to a patient comprising the cells wherein the patient is diagnosed with having an ocular disorder associated with ocular neovascularization or a chronic inflammatory condition.

### Claim 22 (depends on 21)

The method of claim 21, wherein R4, R5, R6, R7, R8, R9, R10, and R11 are hydrogen, such that the compound has the structure of formula (II):

### Claim 23 (depends on 21)

The method of claim 21, wherein x is 1, y is 2, R1 and R2 are methyl, R3 is methyl, and Z is —O—, such that the compound has the structure of formula (2):

### Claim 24 (depends on 21)

The method of claim 21 wherein:
the detecting step comprises detecting pathogenic HIF-1 overexpression in a patient comprising the cells; and
the contacting step comprises administering a therapeutically effective amount of the compound to the patient.

### Claim 25 (depends on 22)

The method of claim 22 wherein:
the detecting step comprises detecting pathogenic HIF-1 overexpression in a patient comprising the cells; and
the contacting step comprises administering a therapeutically effective amount of the compound to the patient.

### Claim 26 (depends on 23)

The method of claim 23 wherein:
the detecting step comprises detecting pathogenic HIF-1 overexpression in a patient comprising the cells; and
the contacting step comprises administering a therapeutically effective amount of the compound to the patient.

### Claim 27 (depends on 24)

The method of claim 24 wherein the detecting step comprises immunodetection of HIF-1α protein.

### Claim 28 (depends on 25)

The method of claim 25 wherein the detecting step comprises immunodetection of HIF-1α protein.

### Claim 29 (depends on 26)

The method of claim 26 wherein the detecting step comprises immunodetection of HIF-1α protein.

### Claim 30 (depends on 24)

The method of claim 24 wherein the patient is diagnosed with having a cancer.

### Claim 31 (depends on 25)

The method of claim 25 wherein the patient is diagnosed with having a cancer.

### Claim 32 (depends on 26)

The method of claim 26 wherein the patient is diagnosed with having a cancer.

### Claim 33 (depends on 24)

The method of claim 24 wherein the patient is diagnosed with having a non-androgen dependent prostate cancer.

### Claim 34 (depends on 25)

The method of claim 25 wherein the patient is diagnosed with having a non-androgen dependent prostate cancer.

### Claim 35 (depends on 26)

The method of claim 26 wherein the patient is diagnosed with having a non-androgen dependent prostate cancer.

### Claim 36 (depends on 27)

The method of claim 27 wherein the patient is diagnosed with having a non-androgen dependent prostate cancer.

### Claim 37 (depends on 28)

The method of claim 28 wherein the patient is diagnosed with having a non-androgen dependent prostate cancer.

### Claim 38 (depends on 29)

The method of claim 29 wherein the patient is diagnosed with having a non-androgen dependent prostate cancer.

### Claim 39 (depends on 21)

The method of claim 21 wherein the contacting step comprises administering a therapeutically effective amount of the compound to a patient comprising the cells wherein the patient is diagnosed with having an ocular disorder associated with ocular neovascularization or a chronic inflammatory condition.

### Claim 40 (depends on 39)

The method of claim 39 wherein the method further comprises the step of detecting pathogenic HIF-1 overexpression in the patient, and the detecting step comprises immunodetection of HIF-1α protein.
